Genmab's Arzerra misses in Phase III for indolent NHL

By Brian Moy | May 24, 2018 | 6:32 PM GMT

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary

Read the full 121 word article

How to gain access

Continue reading with a
two-week free trial.